Not scheduled (OTC for topical formulations); Schedule H for vaginal preparations in some states

Topical (skin), Vaginal (pessary/cream)

• Topical Cream: 1%

• Topical Lotion: 1%

• Topical Dusting Powder: 1%

• Vaginal Cream: 1%, 2%

• Vaginal Tablet/Pessary: 100 mg, 200 mg, 500 mg

• Oral Lozenges/Troches: NOT AVAILABLE in India (for oropharyngeal candidiasis, use nystatin oral suspension or miconazole oral gel instead)

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Superficial Dermatomycoses (Tinea corporis, Tinea cruris, Tinea pedis, Cutaneous candidiasis, Pityriasis versicolor)

Parameter Recommendation

Starting dose Apply 1% cream or lotion to affected area twice daily

Titration Not applicable

Usual maintenance dose Continue twice daily application

Maximum dose Not applicable (topical use)

Duration 2–4 weeks; continue for at least 1 week after clinical resolution

Clinical notes:

• Clean and dry the affected area before application

• Avoid occlusive dressings unless directed

• For intertrigo, apply thinly to prevent maceration

1. Vulvovaginal Candidiasis

Formulation Starting dose Duration Notes

Vaginal cream 1% 5 g intravaginally at bedtime 6–7 nights Applicator provided

Vaginal cream 2% 5 g intravaginally at bedtime 3 nights Higher concentration, shorter course

Pessary 100 mg 1 pessary intravaginally at bedtime 6 nights —

Pessary 200 mg 1 pessary intravaginally at bedtime 3 nights —

Pessary 500 mg Single dose intravaginally Single application Preferred for uncomplicated cases

Parameter Recommendation

Starting dose As per formulation above

Titration Not applicable

Usual maintenance dose Not applicable (short-course therapy)

Maximum dose 500 mg single vaginal dose

Clinical notes:

• Administer at bedtime for optimal retention

• Avoid vaginal douching during treatment

• May weaken latex contraceptives — advise alternative barrier methods

Secondary Indications — Adults Only (Off-label, if any)

Indication Dose Duration Notes Evidence Basis

Candidal balanitis 1% cream applied twice daily 1–2 weeks Consider systemic therapy if recurrent OFF-LABEL — Indian dermatology practice (IADVL protocols)

Otomycosis (fungal otitis externa) 1% solution/cream applied to ear canal once daily 1–2 weeks Specialist only; ensure intact tympanic membrane OFF-LABEL — ENT specialist practice in India

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

1. Candidal Diaper Dermatitis

1 month Apply 1% cream to affected area twice daily 7–14 days Assess for secondary bacterial infection

Parameter Recommendation

Starting dose 1% cream applied twice daily

Titration Not applicable

Usual maintenance dose Continue twice daily until resolution

Maximum dose Not applicable

Clinical notes:

• Avoid prolonged use under occlusive diapers

• Allow skin to air-dry between applications

• If no improvement in 7 days, reassess diagnosis

1. Tinea Infections (Corporis/Cruris/Pedis) in Children

≥2 years Apply 1% cream twice daily 2–4 weeks

Parameter Recommendation

Starting dose 1% cream applied twice daily

Titration Not applicable

Usual maintenance dose Continue for 1 week after clinical clearance

Maximum dose Not applicable

Secondary Indications — Paediatrics (Off-label, if any)

Indication Dose Duration Notes Evidence Basis

Pityriasis versicolor in children ≥2 years 1% cream once daily 2–3 weeks Specialist only OFF-LABEL — IAP/Indian paediatric dermatology practice

⚠️ Age Restriction Statement:

Not recommended in infants <1 month except under specialist supervision. Oral lozenges/troches are NOT AVAILABLE in India; for oropharyngeal candidiasis in children, use nystatin oral suspension or miconazole oral gel.

No adjustment required — negligible systemic absorption with topical and vaginal routes.

Systemic exposure is minimal with all approved routes of administration.

• Known hypersensitivity to clotrimazole or other imidazole antifungals

• Hypersensitivity to any excipient in the formulation

• First trimester of pregnancy (for high-dose vaginal preparations: 500 mg pessary or 2% cream)

• Avoid contact with eyes and mucous membranes (for topical skin preparations)

• Vaginal preparations may damage latex condoms and diaphragms — advise alternative contraception during treatment and for 5 days after

• Discontinue if severe local irritation, burning, or allergic dermatitis develops

• Use with caution in patients with extensive skin erosions (increased absorption)

• Assess for underlying diabetes or immunosuppression if recurrent candidiasis

Aspect Recommendation

Overall safety Topical skin use: Safe throughout pregnancy

Vaginal use: Safe in 2nd and 3rd trimesters

Avoid 500 mg pessary and 2% vaginal cream in 1st trimester

Preferred formulations 1% vaginal cream or 100 mg pessary in pregnancy

Preferred alternatives Miconazole vaginal preparations (if needed)

When to use For symptomatic vulvovaginal candidiasis; benefit outweighs minimal risk

Monitoring Clinical symptom resolution; recurrence is common in pregnancy

Aspect Recommendation

Compatible with breastfeeding Yes — negligible systemic absorption

Preferred alternatives None required; clotrimazole is suitable

Drug levels in milk Negligible (topical/vaginal use)

Infant monitoring If applied near breast area, monitor infant for skin irritation; avoid direct application on nipples before feeds

Aspect Recommendation

Starting dose No adjustment required

Titration Not applicable

Special considerations Aged/fragile skin may be more permeable — apply sparingly

Vaginal atrophy may increase local irritation — consider lower-dose, longer-duration vaginal regimens

Assess renal/hepatic function only if extensive topical use anticipated

Interacting Drug Effect Mechanism Recommendation

Tacrolimus (topical) Potential for increased local immunosuppression Additive effect on skin immunity Avoid concurrent application to same site; if necessary, use under dermatologist supervision

Amphotericin B (topical) Antagonism of antifungal effect Imidazoles may inhibit polyene binding to ergosterol Avoid concurrent topical use on same site

Note: Systemic drug interactions are not clinically significant due to negligible absorption from topical/vaginal routes.

Interacting Drug Effect Recommendation

Nystatin (topical/oral) Potential reduced efficacy of either agent Avoid simultaneous application; space by several hours if both required

Latex contraceptives (condoms/diaphragms) Weakening of latex barrier Advise non-latex alternatives or abstinence during vaginal treatment and for 5 days after

Spermicides Possible inactivation Avoid concurrent use with vaginal clotrimazole

• Local burning or stinging at application site

• Erythema or pruritus

• Vaginal discomfort or irritation (with intravaginal use)

• Skin dryness or peeling (with prolonged topical use)

• Mild contact dermatitis

Adverse Effect Action Required

Severe allergic contact dermatitis Discontinue immediately; consider topical corticosteroid

Anaphylaxis (extremely rare) Discontinue; emergency management as per protocol

Blistering or ulceration Discontinue; specialist referral

Phase Parameters

Baseline Clinical assessment of lesion extent and severity; no laboratory tests required

During treatment Monitor for symptom improvement; assess for local irritation or worsening

Long-term Not intended for prolonged use; if treatment exceeds 4 weeks without resolution, reassess diagnosis and consider specialist referral

Brand Name Manufacturer Formulations

Candid Glenmark Cream, Lotion, Powder, Vaginal tablets

Canesten Bayer Cream, Vaginal cream, Pessaries

Clocip Cipla Cream, Dusting powder

Clotrin Alkem Cream, Vaginal tablets

Imidil GSK/Others Cream

Candizole Various Vaginal tablets

Note: Fixed-dose combinations (FDCs) with beclomethasone or other corticosteroids are available — verify composition before prescribing; avoid steroid-containing FDCs for prolonged use.

NLEM Status: Clotrimazole 1% cream is included in NLEM 2022 (Essential Medicines List); price ceiling may apply.

1. First-line choice: Clotrimazole remains a first-line topical antifungal for superficial dermatophytoses and candidiasis in India due to established efficacy, low cost, and minimal resistance.

1. Duration matters: Continue topical application for at least 1 week beyond clinical cure to prevent relapse — a common prescribing error is premature discontinuation.

1. Avoid steroid-antifungal FDCs: Widespread misuse of clotrimazole-beclomethasone combinations has contributed to tinea incognito in India; use plain clotrimazole whenever possible.

1. Latex warning: Always counsel patients using vaginal clotrimazole about latex contraceptive damage — this interaction is frequently overlooked.

1. Recurrent candidiasis: If vulvovaginal candidiasis recurs ≥4 times/year, screen for diabetes mellitus and consider systemic fluconazole prophylaxis.

1. Not for oral candidiasis in India: Oral lozenges are not marketed in India; use nystatin oral suspension or miconazole oral gel for oropharyngeal candidiasis.

Clotrimazole; topical antifungal; imidazole; tinea; vulvovaginal candidiasis; dermatophytosis; OTC antifungal; pregnancy-safe topical; NLEM India; candidal diaper rash

RxIndia v1.0 — 19 May 2025

• CDSCO approved product inserts

• Indian Pharmacopoeia (IP)

• NLEM India 2022

• IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) treatment guidelines

• API Textbook of Medicine

• IAP (Indian Academy of Pediatrics) guidelines for paediatric dermatoses

• FOGSI guidelines for vulvovaginal candidiasis management

• WHO Model List of Essential Medicines (supportive reference for paediatric formulations)